Jacobs Levy Equity Management
TRDA icon

Jacobs Levy Equity Management’s Entrada Therapeutics TRDA Stock Holding History

Jacobs Levy Equity Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.21M Sell
333,914
-28,872
-8% -$331K 0.02% 453
2025
Q4 		$3.73M Buy
362,786
+46,976
+15% +$396K 0.01% 464
2025
Q3 		$1.83M Buy
315,810
+95,074
+43% +$556K 0.01% 608
2025
Q2 		$1.48M Buy
220,736
+9,863
+5% +$79.4K 0.01% 683
2025
Q1 		$1.91M Sell
210,873
-1,844
-0.9% -$23K 0.01% 669
2024
Q4 		$3.68M Buy
212,717
+10,914
+5% +$198K 0.01% 482
2024
Q3 		$3.22M Buy
201,803
+67,559
+50% +$1.06M 0.01% 512
2024
Q2 		$1.91M Buy
+134,244
New +$1.91M 0.01% 607

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return